Provider Resources for ABILIFY MAINTENA® (aripiprazole)

Treatment support

Once you prescribe ABILIFY MAINTENA for your patients, they can enroll in the Patient Experience Liaison (PEL) program. A PEL is a patient support representative who can speak directly to your patient or caregiver to review treatment access steps, provide guidance on navigating helpful resources, and answer questions about insurance.

PEL Enrollment Form
Give this form to your patients so they can enroll in the program.

Financial support resources

For patients who need additional support paying for their treatment, Otsuka is here to help.

Prescription Savings Card
Helps your commercially insured, eligible* patients save on their prescribed treatment costs.

For help outside the Otsuka network, below is a list of additional financial support options for patients and caregivers.

Patient Access Network Foundation
Helps uninsured patients with out-of-pocket costs and advocates on behalf of patients for improved access and affordability.

HealthWell Foundation
Dedicated to improving access to care for patients who are underinsured by assisting with copays, premiums, deductibles, and out-of-pocket expenses.

The Assistance Fund
Provides patients and their families with financial assistance for their copayments, coinsurance, deductibles, and other health-related expenses.

*Conditions apply. Click to view.

Medicare financial assistance

There are also multiple support options through Medicare. Below is a list of government resources that can provide financial assistance to patients.

Medicare.gov “What’s Covered” App
Delivers accurate cost and coverage information right to a smartphone for a quick and handy reference.

Medicare.gov State Pharmaceutical Assistance Programs
Participating states offer patients financial support for prescription drugs.

Medicare.gov Savings Programs
Assists patients with limited income to pay for their Medicare premiums and other medical expenses.

Medicare.gov Extra Help (Part D)
Helps patients with limited income and resources pay their Medicare prescription drug program costs, like premiums, deductibles, and coinsurance.

Medicare State Health Insurance Assistance Programs
Find programs that educate and assist Medicare-eligible patients, their families, and caregivers through outreach, counseling, and providing access to care and benefits.

Community connections and support resources

Otsuka is here to support your patients on treatment. View available resources that can help connect your patients with communities, patient advocacy groups, research organizations, and support programs.

Explore resources

Patient assistance

Otsuka Patient Assistance Foundation (OPAF)
OPAF is a nonprofit organization that assists underinsured and uninsured patients who have been prescribed Otsuka medications. There are specific eligibility criteria that applicants must meet prior to their approval for assistance. It's important to note that Otsuka America Pharmaceutical, Inc. does not control or influence how OPAF distributes funds.

Otsuka Patient Support™ Health Information Use and
Disclosure Authorization (“Authorization”)

Permission to Use and Disclose Health Information: This Authorization relates to the Otsuka Patient Experience Program and patient experience team. The Program provides services relating to drugs and devices ("Products") of OPH Inc. and its affiliates and successors ("Otsuka"). Your "Providers," for purposes of this Authorization, include any physician, pharmacy, care center, clinic, or other healthcare facilities and professionals, as well as any discount plan, health plan, or other payors that may have information related to the Products you use. By signing this Authorization, you (or your personal representative on your behalf) allow your Providers and Otsuka, along with the Recipients defined below, to use and disclose some of your Protected Health Information as defined below ("PHI") and as described in this Authorization.

PHI Recipients: Your Providers may give your PHI to Otsuka and any Program operators, manufacturers and distributors of the Product, and contractors ("Recipients"). The Recipients can also re-disclose your information to their contractors, vendors, and third parties that may take over the Program in the future. For example, Otsuka may give your information to vendors, advocacy organizations, patient assistance programs, patient access centers, data aggregators, laboratories, safety program administrators, Otsuka Digital Health, other business partners, website tracking tool vendors, and personnel of these third parties. For purposes of this Authorization, “Recipients” include Otsuka and all of these other third parties. “Recipients” also include any legal representatives, caregivers or other contacts listed in this Authorization.

PHI to be Used and Disclosed: PHI includes any and all health information related to the following:

Your name, address, patient ID number, and other demographic data, date of birth, and information you provide on any forms related to the Products
Healthcare records related to your eligibility for and use of the Products, such as dates of treatment, dosage, and dispensing
The healthcare condition for which the Products were or may be prescribed, or your condition while taking or after stopping the Products. You understand that this may include sensitive PHI
Your experience with the Products, including whether you take them as prescribed
Health coverage, financial, payment, and claim information related to the Product or your ability to pay
Information to help support your transition of care, such as getting discharged from a hospital

Purposes: The Recipients may use, share, and re-disclose your PHI, in electronic or any other form or format, for the following purposes:

Determining if you qualify for and contacting you about the Program and Product-related services
Providing assistance to you regarding the Product, facilitating access to the Product, determining health plan coverage requirements, and communicating with you and the Providers regarding the Product, your treatment, or payment for the Product
Internal data collection, research, and reporting, including reviewing utilization, trends, and future needs of patients and providers
Data analysis including de-identifying the PHI, creating limited data sets, or combining it with other information, and monetizing de-identified data as permitted by law
Establishing your treatment profile, tracking coverage, and determining cost sharing
Examining the effectiveness and operation of the Program
Analysis to help evaluate and improve the Program and create new programs
Consistent with applicable law and any applicable standards of ethical conduct, contacting your healthcare provider(s), law enforcement, emergency services, a family member, or any other person reasonably able to assist if a Recipient has a good faith belief that such action is necessary to prevent or lessen a threat to your health or safety, or to the health and safety of others
Fulfilling the Recipients' legal obligations
Using tracking tools on websites and applications to examine your interaction and experience with Program-related or Product-related platforms and to help the websites and applications function
Proper management and administration of the Recipients and the Program, including re-disclosures to other Recipients, Providers, payors, and service providers as needed to operate the Program

Revocation: You may revoke and cancel this Authorization by calling 1-833-468-7852 emailing [email protected], or sending a written notice to Otsuka Patient Support™, 508 Carnegie Center Drive, Princeton, NJ 08540. If you have questions about the Program, you can talk to your Provider and/or call Otsuka Patient Support™ at that number. If a Provider is disclosing PHI for the Program on an ongoing basis, your revocation will take effect with respect to such Provider when they receive notice of your revocation. Revocation will not affect any uses or disclosures of PHI that took place before such cancellation was received. For example, if your PHI has already been shared with third parties, it will not be able to be deleted. If you revoke this Authorization you will no longer be eligible to receive Program services, but this will not affect your ability to receive the Product.

Voluntary Authorization: You do not have to sign this Authorization. Refusal to sign will not affect the start, continuation, or quality of your treatment or any other treatment, payment, enrollment in health plans, or eligibility for benefits for which you qualify. Your Providers may not condition treatment, payment, enrollment, or eligibility for benefits on whether you sign this Authorization.

Re-Disclosure: Once your PHI is disclosed as allowed in this Authorization, it may be re-disclosed by the Recipients and will no longer be protected by the Health Insurance Portability and Accountability Act (HIPAA). Additionally, it may no longer be protected by certain other state and federal privacy and security laws.

Expiration: This Authorization will remain in effect for one (1) year from the date of the signature(s) below or until it is revoked, whichever is earlier.

Copy of Authorization: You have a right to receive a copy of this authorization.

By signing this Authorization, you acknowledge that you have read and understand this Authorization and expressly authorize the uses and disclosures of PHI referenced in this Authorization.

Consent: By signing this Authorization, I acknowledge and confirm that I have read, understand, and agree to this Authorization and expressly authorize the uses and disclosures of PHI referenced in this Authorization.

Individuals signing electronically: By signing this Authorization electronically, you understand that you will receive a copy of your completed Authorization to the email address that you provide. You must let us know if your email or other contact information changes. You understand that your email system may not be a completely secure form of transmission and is not always encrypted. You understand that you may sign a hard copy of this form if you prefer not to sign electronically.

ABILIFY MAINTENA^®

(aripiprazole) for extended-release injectable suspension